Revolution Medicines, Inc. (RVMD) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $149.19: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality; Negative price momentum.
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes... Read more
Sell if holding. Engine safety override at $149.19: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Revolution Medicines, Inc.
Latest news
- NEWS Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220 — benzinga Jun 10, 2026 positive
- NEWS RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182 — benzinga Jun 2, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195 — benzinga Jun 1, 2026 positive
- NEWS Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195 — benzinga Jun 1, 2026 positive
- NEWS Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time — benzinga May 31, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinedaraxonrasib (RASolute 302)10-K Item 1: 'RASolute 302: comparing daraxonrasib against chemotherapy in patients with second line (2L) PDAC; a clinical readout for this study is currently expected in the first half of 2026'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $149.19: Quality below floor (1.7 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $138.90. Score 4.3/10, moderate confidence.
Take-profit target: $167.70 (+12.3% upside). Prior stop was $138.90. Stop-loss: $138.90.
Concentration risk — Pipeline: daraxonrasib (RASolute 302); Quality below floor (1.7 < 4.0).
Revolution Medicines, Inc. trades at a P/E of N/A (forward -26.0). TrendMatrix value score: 6.0/10. Verdict: Sell.
27 analysts cover RVMD with a consensus score of 4.4/5. Average price target: $186.
What does Revolution Medicines, Inc. do?Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset...
Revolution Medicines is a clinical-stage precision oncology company developing RAS(ON) inhibitors. Lead asset daraxonrasib is in multiple Phase 3 trials for pancreatic cancer and NSCLC, with a key readout from RASolute 302 expected in H1 2026. The pipeline also includes zoldonrasib (G12D), elironrasib (G12C), and RMC-5127 (G12V).